Rapid Micro Biosystems, Inc.

Thank you for standing by. My name is Eloisa and I will be your conference operator today. At this time, I would like to welcome everyone to the RAPID Microbiosystems fourth quarter and full year 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by number one on your telephone keypad. If you would like to withdraw your question, press star one again. Thank you.

I would now like to turn the call over to Mike Bowler. Please go ahead.

Good morning, and thank you for joining the Rapid Microbiosystems fourth quarter and full year 2024 earnings call. Joining me on the call are Rob Spignesi, President and Chief Executive Officer, and Sean Werches, Chief Financial Officer. Earlier today, we issued a press release announcing our fourth quarter and full year 2024 financial results. Additionally, last night, in a separate release, we announced a distribution and collaboration agreement with the life science business of Merck KGAA Darmstadt, Germany, which operates in the U.S. as Millipore Sigma. Copies of both releases are available on the company's website at rapidmicrobio.com under investors in the news and events section. Before we begin, I'd like to remind you that many statements made during this call may be considered forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions, including but not limited to statements relating to Rapid Micro's financial condition, assumptions regarding future financial performance, anticipated future cash usage, guidance for 2025, including revenue, expenses, gross margins, system placements, and validation activities, expectations for and planned activities related to Rapid Micro's business development and growth, including our recently announced distribution and collaboration agreement, customer interest and adoption of the Growth Direct system, and statements regarding rapid sterility. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with Rapid Micro's business, please refer to the risk factors section of our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission as updated from time to time in our subsequent filings with the SEC. We urge you to consider these factors and you should be aware that these statements should be considered estimates only and are not a guarantee of future performance. The conference call contains time sensitive information and is accurately only as of the live broadcast today, February 28, 2025. Rapid Micro disclaims any intention or obligation except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or other ones. And with that, I'll turn the call over to Rob. Thank you, Mike.